1.

Record Nr.

UNINA9910138885703321

Autore

Grandbois Alain

Titolo

Correspondance / / Alain Grandbois ; Édition critique par Bernard Chassé

Pubbl/distr/stampa

Presses de l’Université de Montréal, 2003

[Montreal, Quebećbec] : , : Les Presses de l'Université de Montréal, , 2003

©2003

ISBN

2-7606-2958-9

2-8218-5075-1

2-7606-2652-0

1-4593-3532-5

Edizione

[Éd. critique /]

Descrizione fisica

1 online resource (750 p.)

Collana

Bibliothèque du nouveau monde

Disciplina

841/.52

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Comprend un index.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

""52. À Lucienne Boucher, 25 septembre 1932""""53. À Lucienne Boucher, 27 septembre 1932""; ""54. À Lucienne Boucher, 1[sup(er)] octobre 1932""; ""55. À Lucienne Boucher, 3 octobre 1932""; ""56. À Lucienne Boucher, 3 octobre 1932""; ""57. À Lucienne Boucher, 5 octobre 1932""; ""58. À Lucienne Boucher, 7-8 octobre 1932""; ""59. À Lucienne Boucher, 9 octobre 1932""; ""60. À Lucienne Boucher, 10 octobre 1932""; ""61. À Lucienne Boucher, 13 octobre 1932""; ""62. À Lucienne Boucher, 15 octobre 1932""; ""63. À Lucienne Boucher, 17 octobre 1932""

""64. À Lucienne Boucher, 19 octobre 1932""

Sommario/riassunto

Malgré les réticences maintes fois répétées d’Alain Grandbois à l’égard de l’écriture épistolaire, sa correspondance permet de découvrir l’homme par-delà la légende. On y retrace la genèse de son œuvre et des aspects inédits de sa vie mouvementée. Le regard qu’il porte sur son époque et sur ses contemporains par le biais de ses lettres témoigne de ses préoccupations profondes tout autant que de son attitude à l’égard de la société.



2.

Record Nr.

UNINA9910966019903321

Titolo

New frontiers in contraceptive research : a blueprint for action / / Sharyl J. Nass and Jerome F. Strauss III, editors ; Committee on New Frontiers in Contraceptive Research, Board on Health Sciences Policy

Pubbl/distr/stampa

Washington, D.C., : National Academies Press, c2004

ISBN

9786610176663

9780309166539

0309166535

9781280176661

1280176660

9780309528290

0309528291

Edizione

[1st ed.]

Descrizione fisica

1 online resource (xiv, 232 pages) : illustrations

Altri autori (Persone)

NassSharyl J

StraussJerome F, III,  <1947-> (Jerome Frank)

Disciplina

613.9/4/072

Soggetti

Contraception - Research

Birth control - Research

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Nota di bibliografia

Includes bibliographical references.

Nota di contenuto

""Front Matter""; ""Reviewers""; ""Preface""; ""Contents""; ""Executive Summary""; ""1 Introduction""; ""2 Target Discovery and Validation""; ""3 Product Identification and Development""; ""4 Improving Contraceptive Use and Acceptability""; ""5 Capitalizing on Recent Scientific Advances""; ""APPENDIXES""; ""APPENDIX A--Examples of Progress and Impediments in Contraceptive Research and Development""; ""APPENDIX B--Agendas and Participants in Committee Workshops""; ""APPENDIX C--Committee Biographies""; ""Glossary""; ""Acronyms""

Sommario/riassunto

More than a quarter of pregnancies worldwide are unintended. Between 1995 and 2000, nearly 700,000 women died and many more experienced illness, injury, and disability as a result of unintended pregnancy. Children born from unplanned conception are at greater risk of low birth weight, of being abused, and of not receiving sufficient



resources for healthy development. A wider range of contraceptive options is needed to address the changing needs of the populations of the world across the reproductive life cycle, but this unmet need has not been a major priority of the research community and pharmaceutical industry. New Frontiers in Contraceptive Research: A Blueprint for Action , a new report from the Institute of Medicine of the National Academies, identifies priority areas for research to develop new contraceptives. The report highlights new technologies and approaches to biomedical research, including genomics and proteomics, which hold particular promise for developing new products. It also identifies impediments to drug development that must be addressed. Research sponsors, both public and private, will find topics of interest among the recommendations, which are diverse but interconnected and important for improving the range of contraceptive products, their efficacy, and their acceptability.